A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer.
about
Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy?Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patientsClinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activityMoving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic virusesEvidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?Potential for Improving Potency and Specificity of Reovirus Oncolysis with Next-Generation Reovirus VariantsGoing viral: a review of replication-selective oncolytic adenovirusesChemovirotherapy: combining chemotherapeutic treatment with oncolytic virotherapyCancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advancesActivation of p53 by chemotherapeutic agents enhances reovirus oncolysisA phase I trial of single-agent reolysin in patients with relapsed multiple myelomaReovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway.Engineered measles virus Edmonston strain used as a novel oncolytic viral system against human hepatoblastoma.Oncolytic Viruses to Treat Ovarian Cancer Patients - a Review of Results From Clinical TrialsQuantification of the host response proteome after mammalian reovirus T1L infection.Oncolytic reovirus in canine mast cell tumor.A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children's Oncology Group Phase I Consortium reportBase-modified thymidines capable of terminating DNA synthesis are novel bioactive compounds with activity in cancer cells.The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancer.Naturally occurring reoviruses for human cancer therapy.Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma.Reovirus-mediated cytotoxicity and enhancement of innate immune responses against acute myeloid leukemia.The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated micePhase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors.Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin-paclitaxel doublet chemotherapy.Reovirus in cancer therapy: an evidence-based reviewRandomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic AdenocarcinomaReolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer.Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors.Reovirus: a targeted therapeutic--progress and potential.Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms.Oncolytic reovirus type 3 (Dearing) as a novel therapy in head and neck cancer.Review of the impact of antineoplastic therapies on the risk for cholelithiasis and acute cholecystitis.Pharmacological modulation of anti-tumor immunity induced by oncolytic viruses.Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus.The oncolytic virus, pelareorep, as a novel anticancer agent: a review.Asynchronous leptomeningeal carcinomatosis from pancreatic cancer: a case report and review of the literature.Oncolytic viruses: a new class of immunotherapy drugs.Precise scheduling of chemotherapy primes VEGF-producing tumors for successful systemic oncolytic virotherapy.African Swine Fever Virus NP868R Capping Enzyme Promotes Reovirus Rescue during Reverse Genetics by Promoting Reovirus Protein Expression, Virion Assembly, and RNA Incorporation into Infectious Virions.
P2860
Q24596171-4EFAE059-0002-4817-81A5-96CEF469BC4DQ24617027-07AB6712-D144-400E-B5E5-DE1D58273574Q26750568-083F95F2-F282-41D2-85E1-4B8FB1602492Q26752807-271A5ABA-D848-404E-8A5E-96F4832636BBQ26775030-97ADDED1-5613-4502-A8FB-54F4B6B0296DQ26775033-7B9DB9D0-EE2C-488E-AF74-65DB4A10855BQ26797520-F088D884-108D-4A94-9F31-06878E1A8D0EQ26852345-3181A803-220C-4033-B42A-7C3C098CF044Q26863779-34A017C4-0BEB-4EFE-A76A-14E48512EB8FQ28485141-FEB4C475-0C89-459E-B12D-1A5D46CFC1DCQ33418048-9F2FE89E-F50F-4CEC-9795-380B0E1E2B92Q34393001-D22EB838-5C92-4E52-AF4C-CDC68CF4ED5EQ34421151-65613EAE-EEC7-4518-8F61-DB8812EF1E13Q34432804-B28178CA-4F6E-4D43-BCF7-ED20A2A7525AQ34512626-3C8EB06F-C45E-4C14-8DAD-21A8B82FDEE9Q35000631-94C6C0A9-30FD-471C-9054-D594175FA97AQ35224368-C5B6733A-8FB7-4E51-A591-ABAAC626C994Q35236168-AD46853A-7ED1-40AF-869F-351794BE2297Q35686522-1BADE6D3-7E98-4919-9049-3B5D55BD4AEFQ36078485-440FA3FC-B19A-43B4-A898-EDCDE22DAE4EQ36298608-54B85C48-978D-41C9-878E-00B5192370B3Q36574519-9488CA22-889A-4679-81B8-BA9EDD13FC34Q36673729-4A9F74F1-F3C1-47BA-B76D-E261B4CB61FEQ36766032-8E3A7D93-68DB-4251-AD79-F276EE3CDAB6Q36766052-9FD11F2A-1812-4075-B1C2-B973500FCA24Q37031909-5471280F-88F9-4E23-8989-E8008ABA2F15Q37043514-94D0F806-D6C9-4262-B526-5A9A4E9F282CQ37062074-B1AAC696-F712-4F7D-8D9B-1C0543A189DCQ37347236-FFDD5790-3F4F-4688-86B8-F98CF5DA3D4EQ37360608-017399B2-84B5-4CA7-8195-EF4BBB18085EQ37459636-EF461757-43AD-4D16-A4DF-12354904AE59Q38058884-A361B4CE-404E-4AE4-B790-85DC1D07B929Q38151492-1623878E-3678-4224-940D-944463BA7A54Q38237657-93214DDF-853A-4E0A-9795-7A73429F4361Q38315523-62B5090E-9BB2-44C7-B5DB-74B4599EC1D5Q38360781-241BA9F8-95A5-4B10-BA35-93F84966A7EFQ38548938-6C9DF0FC-3F0F-4C75-9A2E-72091D3FFD3BQ38577450-C7F0BCA2-4210-41D9-9CB7-EAEE47B330A3Q38647883-01ACC041-C804-4D72-8371-32C3A16D7EADQ38712130-6F85481C-A5AD-4B28-A93E-F69D3FD4B366
P2860
A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
A phase I study of the combina ...... patients with advanced cancer.
@ast
A phase I study of the combina ...... patients with advanced cancer.
@en
A phase I study of the combina ...... patients with advanced cancer.
@nl
type
label
A phase I study of the combina ...... patients with advanced cancer.
@ast
A phase I study of the combina ...... patients with advanced cancer.
@en
A phase I study of the combina ...... patients with advanced cancer.
@nl
prefLabel
A phase I study of the combina ...... patients with advanced cancer.
@ast
A phase I study of the combina ...... patients with advanced cancer.
@en
A phase I study of the combina ...... patients with advanced cancer.
@nl
P2093
P1476
A phase I study of the combina ...... patients with advanced cancer.
@en
P2093
George Gill
Hendrik-Tobias Arkenau
Johann S de Bono
Karl Mettinger
Katie Twigger
Kevin Harrington
Martijn P Lolkema
Matt Coffey
Patricia Roxburgh
Rosemary Morrison
P304
P356
10.1158/1078-0432.CCR-10-2159
P407
P577
2010-11-24T00:00:00Z